Following clinical validation of translational inhibitors targeting two important NSCLC oncogenic drivers, epidermal growth factor receptor (EGFR) [15,16,17,18] and anaplastic lymphoma kinase (ALK) [19,20,21], molecular-targeted therapies have been applied to the management of metastatic NSCLC, resulting in remarkably improved prognosis and quality of life relative to patients treated with conventional chemotherapeutics [22,23,24]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.